MYD88 and rheumatoid arthritis: Gene expression profile assay (Fig. 5A) revealed that among naive to treatment RA, subjects with BMI ≥ 25 Kg/m2 showed significant over-expression of CCL3 (5.23 fold; p = 0.02), CCR1 (2.07 fold; p = 0.03), CCR2 (2.90 fold; p = 0.02), FAS-L (5.77 fold; p = 0.03) and MyD88 (4.33 fold; p = 0.02) compared to RA patients in sustained clinical and ultrasound remission with BMI < 25 Kg/m2 (Fig. 5B–G).